Fibroblast Growth Factor-Peptide Promotes Bone Marrow Recovery After Irradiation

  • Jun Ma
  • Yanqian Hou
  • Deping Han
  • Mei Zhang
  • Chun Chen
  • Bingrong Zhang
  • Zhenhuan Zhang
  • Xiaohui Wang
  • Shanmin Yang
  • Yansong Guo
  • Paul Okunieff
  • Lurong Zhang
Conference paper
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 765)

Abstract

Various members of the fibroblast growth factor (FGF) family mitigate radiation-induced damage. We designed and synthesized the binding domain peptide of FGF-2 (FGF-P) with a dimer form resistant to peptidase and examined its mitigatory effect on murine bone marrow cells. NIH Swiss mice were exposed to different doses of total body irradiation (TBI) and treated with ten doses of 5 mg/kg FGF-P. We achieved the following results: (1) FGF-P stimulated the growth of bone marrow cells harvested from mice exposed to 3 Gy; (2) on day 25 after 6 Gy TBI, the number of leukocytes and granulocytes was higher in the FGF-P group than in the vehicle-alone group; (3) FGF-P significantly increased the number of pro-B and pre-B cells; and (4) FGF-P treatment in vivo increased the long-term hematopoietic stem cells (LT-HSC) in bone marrow. These data reveal the underlying mechanism by which FGF-P rescued a significant percentage of the exposed mice. The increase of LT-HSC in bone marrow leads to a concomitant increase of pro-B and pre-B cells followed by leukocytes and granulocytes, which in turn enhance immunity against infection.

Keywords

Bone marrow recovery Fibroblast growth factor-peptide Irradiation 

Notes

Acknowledgments

This project is supported in part by U19 AI067733, RC1AI078519, RC2-AI-087580, RC1-AI081274 (NIAID/NIH), and Shands Cancer Center startup funds (University of Florida). We thank Dr. Chihray Liu and the medical physics faculty at UF for ensuring dosimetric accuracy in these experiments and Kate Casey-Sawicki for editing this manuscript.

References

  1. 1.
    Herodin F, Grenier N, Drouet M (2007) Revisiting therapeutic strategies in radiation casualties. Exp Hematol 35:28–33CrossRefPubMedGoogle Scholar
  2. 2.
    TMT handbook. http://www.tmthandbook.org/. 18 Jul 2011
  3. 3.
    Layton JE, Hall NE, Connell F et al (2001) Identification of ligand-binding site III on the immunoglobulin-like domain of the granulocyte colony-stimulating factor receptor. J Biol Chem 276:36779–36787CrossRefPubMedGoogle Scholar
  4. 4.
    Lin X, Takahashi K, Campion SL et al (2006) Synthetic peptide F2A4-K-NS mimics fibroblast growth factor-2 in vitro and is angiogenic in vivo. Int J Mol Med 17:833–839PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Jun Ma
    • 1
  • Yanqian Hou
    • 2
  • Deping Han
    • 3
  • Mei Zhang
    • 3
  • Chun Chen
    • 3
  • Bingrong Zhang
    • 3
  • Zhenhuan Zhang
    • 3
  • Xiaohui Wang
    • 3
  • Shanmin Yang
    • 3
  • Yansong Guo
    • 3
  • Paul Okunieff
    • 3
  • Lurong Zhang
    • 3
  1. 1.Institute of Digestive DiseasesZhengzhou UniversityHenanChina
  2. 2.Department of Laboratory MedicineKongjiang HospitalShanghaiChina
  3. 3.Department of Radiation Oncology, UF Shands Cancer CenterUniversity of FloridaGainesvilleUSA

Personalised recommendations